Ask AI
APPLexus CLL/SLL

CE / CME

Optimizing CLL/SLL Care: Expert Strategies for APPs to Integrate New Targeted Therapies and Practice-Changing Evidence

Nurse Practitioners/Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: September 19, 2025

Expiration: April 01, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How confident do you feel in counseling patients with chronic lymphocytic leukemia (CLL) to effectively engage them in their care with the goal of promoting adherence to their treatment plan?

2.

Based on available evidence from head-to-head comparative phase III trials, which of the following pairs of BTK inhibitors would you tell a patient is associated with a similar risk for hypertension?

3.

A 68-year-old woman with CLL harboring del(17p) and a history of clinical depression, atrial fibrillation, and controlled headaches was treated with triplet therapy consisting of venetoclax, acalabrutinib, and obinutuzumab. Despite an initial partial remission, her measurable residual disease remained detectable throughout treatment. After 18 months, she presented with disease progression, characterized by progressive lymphadenopathy, an increased lymphocyte count, and new cytopenias. Genetic testing revealed the presence of the acquired BTK C481S mutation.

Considering available information, which of the following is the best next-line of therapy for this patient?

4.

Allopurinol and hydration are important adverse risk mitigation strategies used for which of the following therapies used in CLL management?